Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. There is no approved vaccine currently available against CCHF. The most promising candidate, which has previously been shown to confer protection in the small animal model, is a modified Vaccinia Ankara virus vector expressing the CCHF viral glycoprotein (MVA-GP). It has been shown that MVA-GP induces both humoral and cellular immunogenicity. In the present study, sera and T-lymphocytes were passively and adoptively transferred into recipient mice prior to challenge with CCHF virus. Results demonstrated that mediators from both arms of the immune system were required to demonstrate protective effects against lethal challenge.

Original publication

DOI

10.1371/journal.pone.0156637

Type

Journal article

Journal

PloS one

Publication Date

01/2016

Volume

11

Addresses

Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.

Keywords

Cell Line, Animals, Humans, Mice, Vaccinia virus, Hemorrhagic Fever Virus, Crimean-Congo, Hemorrhagic Fever, Crimean, Glycoproteins, Viral Proteins, Viral Vaccines, Immunity, Cellular, Africa, Asia, Middle East, Europe, Eastern, Immunity, Humoral